Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  NovoCure Limited    NVCR   JE00BYSS4X48

NOVOCURE LIMITED

(NVCR)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/25/2020 11/27/2020 11/30/2020 12/01/2020 12/02/2020 Date
116.68(c) 126.84(c) 125.65(c) 126.97(c) 130.22(c) Last
1 788 616 844 039 5 538 280 657 894 774 264 Volume
-2.29% +8.71% -0.94% +1.05% +2.56% Change
More quotes
Financials (USD)
Sales 2020 483 M - -
Net income 2020 23,7 M - -
Net cash position 2020 160 M - -
P/E ratio 2020 589x
Yield 2020 -
Sales 2021 576 M - -
Net income 2021 46,5 M - -
Net cash position 2021 318 M - -
P/E ratio 2021 313x
Yield 2021 -
Capitalization 13 256 M 13 256 M -
EV / Sales 2020 27,1x
EV / Sales 2021 22,5x
Nbr of Employees 782
Free-Float 83,6%
More Financials
Company
NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through... 
Sector
Medical Equipment, Supplies & Distribution
Calendar
12/02 | 11:20amPresentation
More about the company
Notations Surperformance© of NovoCure Limited
Trading Rating : Investor Rating :
More Ratings
All news about NOVOCURE LIMITED
11/25NOVOCURE : to Participate in the Evercore ISI 2020 Virtual HealthCONx Conference
BU
11/19NOVOCURE : Announces 43 Presentations on Tumor Treating Fields at Society for Ne..
BU
11/11NOVOCURE : Receives CE Mark for NovoTTF-100L™ System
BU
11/10NOVOCURE : Announces Agenda for Virtual Research and Development Day
BU
11/09NOVOCURE : Announces Closing of $150 Million Revolving Credit Facility with a Sy..
BU
11/05NOVOCURE : Announces Closing of $575 Million 0% Convertible Senior Notes Private..
BU
11/02NOVOCURE : Prices $500 Million 0% Convertible Senior Notes Private Placement
BU
11/02NOVOCURE : Announces Proposed Private Placement of $500 Million of Convertible S..
BU
10/29NOVOCURE : Announces Strategic Alliance with NYU Grossman School of Medicine for..
BU
10/29NOVOCURE : Reports Third Quarter 2020 Financial Results and Provides Company Upd..
BU
10/02NOVOCURE : to Report Third Quarter 2020 Financial Results
BU
09/29NOVOCURE : to Host Virtual Research & Development Day
BU
09/25NOVOCURE : Honors Mesothelioma Day with Activities to Raise Awareness of Mesothe..
BU
09/04NOVOCURE : to Participate in the 2020 Wells Fargo Virtual Healthcare Conference
BU
08/13NOVOCURE : Announces Expansion of Its Executive Leadership Team
BU
More news
News in other languages on NOVOCURE LIMITED
11/16NOVOCURE : Prüfungsausschuss beschließt Erstattung medizinischer Leistungen für ..
07/15MERCK : collaboration pour des essais cliniques avec Novocure
03/27NOVOCURE : Gemeinsamer Bundesausschuss beschließt Aufnahme von TTFields in die R..
01/27VIRUS CHINOIS : le nombre de cas pourrait être supérieur à 40'000 (chercheurs)
2019NOVOCURE : Deutsches Institut für Qualität und Wirtschaftlichkeit im Gesundheits..
More news
Chart NOVOCURE LIMITED
Duration : Period :
NovoCure Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVOCURE LIMITED
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 9
Average target price 126,00 $
Last Close Price 130,22 $
Spread / Highest target 53,6%
Spread / Average Target -3,24%
Spread / Lowest Target -34,0%
EPS Revisions
Managers
NameTitle
Asaf Danziger Chief Executive Officer & Director
William F. Doyle Executive Chairman
Wilhelmus Groenhuysen Chief Operating Officer
Ashley Cordova Chief Financial Officer, SVP-Investor Relations
Uri Weinberg Chief Science Officer
Sector and Competitors
1st jan.Capitalization (M$)
NOVOCURE LIMITED50.67%12 925
MASIMO CORPORATION60.11%13 933
ASAHI INTECC CO., LTD.14.06%9 253
PENUMBRA, INC.31.72%7 857
GETINGE AB4.34%5 821
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.39.67%4 319